Figure 5.

Src–YAP blockade by EGFR-TKIs, MAPK, PI3K, Rho/ROCK, and STAT3 inhibitors, Src inhibitor, YAP–TEAD complex inhibitor, and cyclin-dependent kinase (CDK) 1, 7, and 9 inhibitors, which could be potential future targets in therapies for the treatment of NSCLC.